The Marks Family Scholarship for
Undergraduate Research
The Marks Family Scholarship is the result
of a generous donation from Dr. G. Lynn Marks and Mrs.
Cheryl Marks to the College of Sciences and Mathematics
and the Department of Chemistry and Biochemistry with a
match provided by GlaxoSmithKline Pharmaceuticals. The
scholarship provides funds for highly qualified
undergraduate students to carry out research in the
Goodwin Laboratory on subjects related to M.
tuberculosis and other infectious diseases. As such,
this scholarship dovetails with our two main research
projects. The first is in KatG, an enzyme that figures
prominently in the defenses of pathogenic organisms
against host immune-derived hydrogen peroxide. The second
is in targeting the enzymes of the shikimate pathway for
development of new anti-tubercular agents. We offer our
sincere thanks to Dr. and Mrs. Marks and GSK
Pharmaceuticals for their generosity on behalf of these
young scientists.
Marks Family Scholars
2023 - 2024 Louisa Forbes,
Sophomore, B.S. Biochemistry
2021 - 2023 Ryan Mumford, B.S.
Biochemistry
2021 - 2022 Nina Orihuela, B.A.,
Chemistry (Pre-Med option)
2020 - 2021 Aishah Lee, B.S.,
Biochemistry
2019 - 2020 Laura Minton, B.S.,
Biomedical Sciences
2018 - 2019 Savannah Petrus, B.S.,
Biochemistry
2016 - 2018 Patrick Sahrmann, B.S.,
Biochemistry
2015 - 2016 Olivia Snider, B.S.
Biochemistry
2014 - 2015 Lauren Barr, B.S.
Biomedical Sciences
About Dr. Marks
Dr. Lynn Marks obtained his Bachelor of Science in Chemistry
from Auburn University in 1979. He then earned his Medical
Doctorate from the University of South Alabama in 1983. He
completed a residency in Internal Medicine as well as a fellowship
in Infectious Disease, earning board certification in each. Dr.
Marks served on the faculty of the University of South Alabama
College of Medicine after which he began work for GlaxoSmithKline
Pharmaceuticals. Dr. Marks rose to Senior Vice President,
Medicines Development Centre for Infections Disease, and then
became Senior Vice President of Projects, Clinical Platforms, and
Sciences. His team was accountable for delivering the global
medicines portfolio, Phase I - IV, of clinical trials involving
over 50 countries and numerous disease areas. He has recently retired from GlaxoSmithKline.